Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor which has been implicated in numerous solid and hematologic cancers. ALK mutations are reported in about 5-7% of neuroblastoma cases but the ALK-positive percentage increases significantly in the relapsed patient population. Crizotinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Siaw, Joachim T., Wan, Haiying, Pfeifer, Kathrin, Rivera, Victor M., Guan, Jikui, Palmer, Ruth H., Hallberg, Bengt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045374/
https://www.ncbi.nlm.nih.gov/pubmed/27049722
http://dx.doi.org/10.18632/oncotarget.8508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045374/
https://www.ncbi.nlm.nih.gov/pubmed/27049722
http://dx.doi.org/10.18632/oncotarget.8508

Ejemplares similares